<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02595359</url>
  </required_header>
  <id_info>
    <org_study_id>0001</org_study_id>
    <nct_id>NCT02595359</nct_id>
  </id_info>
  <brief_title>Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis</brief_title>
  <official_title>Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Federal de Pernambuco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidade Federal de Pernambuco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to evaluate the efficacy and safety of the prophylactic effect of
      intracameral moxifloxacin for prevention of postcataract endophthalmitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although cataract surgery is generally considered a safe procedure resulting in a favourable
      visual outcome, surgical complications do occur. The most feared complication is
      postoperative endophthalmitis which is an infectious condition caused by micro-organisms
      introduced to the interior of the eye during or after the surgical procedure.

      As endophthalmitis is an infection, it should be preventable by antibiotic treatment.

      Prophylactic antibiotic treatment can be given as topical treatment preoperatively, or during
      surgery directly into the anterior chamber, or as a subconjunctival, or it can be given as
      topical treatment postoperatively.

      The aim of this study was to evaluate the efficacy and safety of the prophylactic effect of
      intracameral moxifloxacin for prevention of postcataract endophthalmitis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>endothelial cell count</measure>
    <time_frame>6-month; 1 year; 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>endophthalmitis incidence</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Endophthalmitis</condition>
  <arm_group>
    <arm_group_label>moxifloxacin intracameral</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>moxifloxacin injection given at conclusion of cataract intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Moxifloxacin intracameral</description>
    <arm_group_label>moxifloxacin intracameral</arm_group_label>
    <other_name>Vigamox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of visually significant cataract

        Exclusion Criteria:

          -  Has known allergies to moxifloxacin

          -  Has significant ocular co-morbidities in one or both eyes which may include (but is
             not limited to): advanced glaucoma, advanced or active macular degeneration, Fuchs
             corneal dystrophy, prior corneal transplantation, advanced diabetic eye disease,
             history of retinal detachment or any patient that would require billing a complex
             cataract procedure for any reason

          -  Has a known history of a condition which causes an immuno-compromised host state
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rodrigo Lira</last_name>
    <role>Principal Investigator</role>
    <affiliation>Prof</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rodrigo Lira, MD</last_name>
    <phone>+5581999760274</phone>
    <email>rodrigopclira@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rodrigo Lira</last_name>
    <phone>+5581999760274</phone>
    <email>rodrigopclira@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UFPE Ophthalmology</name>
      <address>
        <city>Recife</city>
        <state>PE</state>
        <zip>50740600</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodrigo Lira, MD</last_name>
      <phone>5581999760274</phone>
      <email>rodrigopclira@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2015</study_first_submitted>
  <study_first_submitted_qc>November 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2015</study_first_posted>
  <last_update_submitted>May 1, 2017</last_update_submitted>
  <last_update_submitted_qc>May 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade Federal de Pernambuco</investigator_affiliation>
    <investigator_full_name>Rodrigo Pessoa Cavalcanti Lira</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>endophthalmitis</keyword>
  <keyword>antibiotic therapy</keyword>
  <keyword>cataract surgery</keyword>
  <keyword>prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endophthalmitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>undecided</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

